Sherwin Kuo

Sherwin Kuo practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Sherwin Kuo's NPI, 1245762970, was assigned on March 31, 2017. Sherwin Kuo holds California license A167223.

Sherwin Kuo's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Sherwin Kuo's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Sherwin Kuo is also affiliated with Cedars-Sinai Marina Hospital. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Sherwin Kuo to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sherwin Kuo practices, 2 sites in all. Vendor and product names are available with a free account.

Hospitalist is Sherwin Kuo's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Sherwin Kuo is licensed in California.

CMS data shows 660 Medicare services from Sherwin Kuo across 4 procedure codes in 2024, for 279 Medicare patients. Medicare paid $67,592 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 279 Medicare patients who saw Sherwin Kuo in 2024. The largest group is 75 to 84, with 96 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sherwin Kuo's median patient age at 71, with 55% women.

In 2024, Sherwin Kuo wrote 224 Medicare Part D claims for 86 patients. 89% of them were for generic drugs. CMS names the drug for 47 of them, across 3 drugs with 11 or more claims each, at $565 in total drug cost. In 2023, CMS named 40 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Sherwin Kuo for performance year 2024, reported as part of a group. Sherwin Kuo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Sherwin Kuo, published from 2013 to 2022. 2013 was the busiest year, with 2. The most frequent topics are Fermentation, Glycerol and Microbiota. Sherwin Kuo's most frequent co-authors are Richard L. Gallo, MD, PhD, Alpesh Navin Amin, MD and Alvin Bob Coda, MD.

CMS Open Payments shows 5 general payments to Sherwin Kuo from 4 drug and device companies from 2018 to 2023. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $185.